Biodegradable polymersomes encapsulating copper peroxide and gemcitabine for targeted chemoimmunotherapy

Read full text
Authors: M. LEE, Weiwei Jiang, Jack Chun Hin Chen, Wai Wing Cheng, Ellen Poon, Hiu Yee Kwan, Hung‐Wing Li
Cited by: 3
References: 26

Abstract

Herein, we engineered biodegradable, ROS-responsive polymersomes (HA-PGC) encapsulating gemcitabine (GEM) and copper peroxide nanoparticles (CuO₂), functionalized with hyaluronic acid (HA) to target CD44-overexpressing TNBC cells. Upon reaching the acidic TME, CuO₂ decomposes to generate hydrogen peroxide (H₂O₂) and Cu 2+ ions, triggering robust ROS production via a Cu-based Fenton-like reaction. Elevated ROS simultaneously suppresses cytidine deaminase (CDA), enhancing GEM activation, and depletes glutathione (GSH), reducing ROS scavenging. The induced oxidative stress further promotes immunogenic cell death (ICD), facilitating dendritic cell maturation and enhancing tumor-infiltrating lymphocytes. Consequently, HA-PGC nanoparticles effectively convert cold tumors into hot tumors, significantly improving anti-PD-L1 immunotherapy efficacy. We demonstrated a novel, multifunctional nanoparticle platform combining chemodynamic therapy and immunotherapy, presenting a promising strategy to overcome resistance in triple-negative breast cancer treatment and guide future intelligent immunotherapeutic system design. • Biodegradable polymersomes (HA-PGC) co-encapsulating gemcitabine (GEM) and copper peroxide (CuO₂) nanoparticles was developed. • HA-PGC was functionalized with hyaluronic acid (HA) for active tumor targeting. • The polymersomes disassemble, releasing GEM and CuO₂ under acidic tumor environment. • HA-PGC effectively suppresses tumor growth in 4 T1-bearing mice and converts immunologically “cold” tumors into “hot” tumors. • This tumor responsive nanoplatform integrates chemodynamic therapy with immunotherapy.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Nanoparticle-Based Drug Delivery Advanced Polymer Synthesis and Characterization

Publication details

Journal / source
Journal of Controlled Release
Publisher
Elsevier BV
Volume
393
Pages
114772–114772
Publication date
3 March 2026
Language
EN